The stock's new peak price of Rs.1603.6 was recorded during trading today, marking a notable advance from its 52-week low of Rs.610. Despite a slight intraday pullback with the stock touching a low of Rs.1557.2, Tatva Chintan Pharma Chem remains positioned above its key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical positioning indicates a robust upward trend over multiple time frames.
In comparison, the broader market index, Sensex, experienced a decline of 0.34% today, trading at 84,658.47 points after opening higher. The Sensex remains close to its own 52-week high, just 0.75% shy of 85,290.06, and is trading above its 50-day and 200-day moving averages, signalling a generally bullish market environment. However, Tatva Chintan Pharma Chem's performance has outpaced the market significantly over the last year.
While markets shift, this one's charging ahead! This small-cap from Specialty Chemicals shows the strongest momentum signals in current conditions. Don't miss out on this ride!
- Strongest current momentum
- Market-cycle outperformer
- Specialty Chemicals sector strength
Over the past 12 months, Tatva Chintan Pharma Chem has delivered a return of 88.34%, substantially exceeding the Sensex's 9.46% return and the BSE500's 8.34% return for the same period. This outperformance highlights the stock's resilience and appeal within the Specialty Chemicals sector. The company's market capitalisation grade stands at 3, reflecting its mid-cap status within the industry.
Financially, the company reported a net profit growth of 49.17% in its September quarter, accompanied by its highest quarterly PBDIT of Rs.22.22 crore. Operating profit to net sales ratio for the quarter reached 17.99%, while profit before tax excluding other income was Rs.12.65 crore, both representing peak quarterly figures. These metrics illustrate the company's capacity to generate strong earnings and operational efficiency in recent quarters.
Tatva Chintan Pharma Chem maintains a low average debt-to-equity ratio of 0.03 times, indicating a conservative capital structure with limited reliance on debt financing. The majority shareholding remains with promoters, underscoring stable ownership and governance.
Thinking about Tatva Chintan Pharma Chem ? Our real-time Verdict report breaks down everything – from financial health and peer comparison to technical signals and fair valuation for this small-cap stock!
- Real-time Verdict available
- Financial health breakdown
- Fair valuation calculated
Despite the recent rally, some long-term financial indicators suggest caution. The company’s operating profit has shown a compound annual decline of 30.99% over the past five years. Additionally, the return on equity (ROE) stands at 2.4%, while the price-to-book value ratio is 5.1, indicating a premium valuation relative to peers. The price-to-earnings-to-growth (PEG) ratio is notably high at 210.3, reflecting the disparity between price appreciation and profit growth, which has been modest at 0.7% over the last year.
On the trading day of the new 52-week high, Tatva Chintan Pharma Chem underperformed its sector by 1.01%, and the stock price declined by 1.92% from the previous close after two consecutive days of gains. This short-term correction follows the strong upward momentum that propelled the stock to its current peak.
Overall, Tatva Chintan Pharma Chem’s attainment of a new 52-week high at Rs.1603.6 reflects a significant milestone driven by strong quarterly earnings, solid technical positioning, and sustained outperformance relative to the broader market and sector peers. The stock’s trajectory over the past year demonstrates notable momentum within the Specialty Chemicals industry, supported by key financial metrics and a conservative capital structure.
Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →
